Corporate
Outlook: Positive
Action date: 04/17/2020
Rating action: Upgrade

PHARMA MAR SA

PharmaMar specializes in biotechnology industry and is focused on developing anti-tumour drugs. This group, with an international footprint, is present in the main oncology markets and has a pharmaceutical pipeline with a drug in an advanced stage of development, which is expected to be commercialised in the short-term. Its turnover amounted to € 85.8MM in 2019, with a negative EBITDA (-€ 9.5MM) and unbalanced indebtedness, reaching its results positive values in the first quarter of 2020 following the strategic goals achieved.

Rating

Solicited
Date last rating: 04/17/2020
Date first rating: 05/20/2015